Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in SLE-Associated Immune Thrombocytopenia
NCT07657793Phase 3Recruiting
- Sponsor
- Chinese SLE Treatment And Research Group
- Start
- Jun 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Sirolimus Arm with Placebo Arm (2 arms). Primary endpoint: Overall Response Rate at 24 weeks. Started Jun 2026; status: recruiting.
02
Drugs
sirolimus
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07657793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07657793.